Patients' experiences with pre-test genetic counseling provided by breast cancer healthcare professionals: Results from a large prospective multicenter study.

[1]  M. Piccart,et al.  Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Zweemer,et al.  Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing , 2022, Hereditary cancer in clinical practice.

[3]  S. Seal,et al.  A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland , 2022, Familial Cancer.

[4]  Y. Joly,et al.  Integrating hereditary breast and ovarian cancer genetic counselling and testing into mainstream clinical practice: Legal and ethical challenges. , 2022, Critical reviews in oncology/hematology.

[5]  S. Teo,et al.  Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a low‐to‐middle income Asian country , 2022, Journal of genetic counseling.

[6]  E. Schlichting,et al.  “It was an important part of my treatment”: a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing , 2022, Hereditary cancer in clinical practice.

[7]  L. Kiemeney,et al.  The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care—A Systematic Review , 2022, Cancers.

[8]  R. Gelber,et al.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.

[9]  R. Kim,et al.  A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care , 2021, Current oncology.

[10]  P. James,et al.  Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre , 2021, European Journal of Human Genetics.

[11]  F. Coulet,et al.  Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic , 2020, European Journal of Medical Genetics.

[12]  D. Macmillan,et al.  Changing practice: moving to a specialist nurse-led service for BRCA gene testing. , 2020, British journal of nursing.

[13]  L. Horvath,et al.  Mainstream consent programs for genetic counseling in cancer patients: A systematic review , 2020, Asia-Pacific journal of clinical oncology.

[14]  M. Somerfield,et al.  Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  A. Karsan,et al.  Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System , 2020, Cancers.

[17]  J. Ledermann,et al.  Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process , 2019, International Journal of Gynecological Cancer.

[18]  E. Schlichting,et al.  Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway , 2019, Familial Cancer.

[19]  Nazneen Rahman,et al.  Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer , 2019, JAMA network open.

[20]  J. Garber,et al.  BRCA1/2 testing: therapeutic implications for breast cancer management , 2018, British Journal of Cancer.

[21]  M. Porteous,et al.  Patients’ Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing , 2018, Journal of Genetic Counseling.

[22]  Gloria S. Huang,et al.  Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Stephanie A Cohen,et al.  The past, present and future of service delivery in genetic counseling: Keeping up in the era of precision medicine , 2018, American journal of medical genetics. Part C, Seminars in medical genetics.

[24]  R. Bennett,et al.  Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce Study , 2018, Journal of Genetic Counseling.

[25]  N. Aaronson,et al.  Rapid genetic counseling and testing in newly diagnosed breast cancer: Patients’ and health professionals’ attitudes, experiences, and evaluation of effects on treatment decision making , 2017, Journal of surgical oncology.

[26]  C. Childers,et al.  National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Cardoso,et al.  Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  S. Seal,et al.  Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients , 2016, Scientific Reports.

[29]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.